Everything drug pricing and policy, every day
And the reality that MFN may mean poor access in Europe, not lower prices in the U.S., begins to sink in
And a new resource that makes plain the extent -- and variability -- of hospital markups on pharmaceuticals
And CMS ‘explanations’ for Medicare drug pricing suggest drugmakers and CMS didn’t see eye-to-eye in half of all ‘negotiations’
And CMS extends the deadline for its MFN-in-Medicaid program in an effort to get small- and mid-size companies on board
And STAT digs into drugmaker annual reports and finds that some MFN deals are not yet finalized
And the government takes pharma’s side in the debate over state regulation of 340B contract pharmacies
And looking at public comments on how CMS’ GLOBE and GUARD models will harm innovation
And the odds that Trump mentions TrumpRx in his State of the Union speech are at 88% and rising
And 340B warps everything ... even local property taxes
